Complete Phase 1 safety and pharmacokinetic study of STS101 5.2 mg and two higher doses
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Second Quarter 2021 – Complete Phase 1 safety and pharmacokinetic study with STS101 5.2 mg and two higher dose strengths”
What we found
Evidence strength A What the grades mean
Later 10-Q and 10-K filings state the Phase 1 study of STS101 5.2 mg and two higher doses was completed in June 2021, within the Q2 2021 deadline.
-
A Satsuma Pharmaceuticals, Inc. 10-Q filed 2021-08-10
“a Phase 1 trial, which we completed in June 2021, to evaluate the pharmacokinetics, safety and tolerability of STS101 5.2 mg and two higher dose strengths” ✓ confirmed on the page
-
A Satsuma Pharmaceuticals, Inc. 10-K filed 2022-03-15
“a Phase 1 trial, which we completed in June 2021, to evaluate the pharmacokinetics, safety and tolerability of STS101 5.2 mg and two higher dose strengths” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Phase 1 safety and pharmacokinetic study of STS101
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Satsuma Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C692830-024820 · Corrections policy